NCT00102011CompletedPhase 3
Colonoscopy or Fecal Occult Blood Test in Screening Healthy Participants for Colorectal Cancer
Colonoscopy Screening Trial
Source: ClinicalTrials.gov · Last updated 9 Mar 2026
Brief summary (registry, in English)
RATIONALE: Screening tests, such as colonoscopy and fecal occult blood test, may help doctors find tumor cells early and plan better treatment for colorectal cancer. PURPOSE: This randomized phase III trial is studying colonoscopy to see how well it works compared to fecal occult blood test in screening healthy participants for colorectal cancer.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 4952 (estimated)
- First submitted
- 18 Jan 2005
- Start date
- 25 May 2000
- Primary completion date
- 5 Mar 2026
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Colorectal cancer
- NCT number
- NCT00102011
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 4952
- From 25 May 2000 to the primary completion date, 5 Mar 2026
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- DISEASE CHARACTERISTICS:
- Healthy participants at average risk for developing colorectal cancer
- No history of colorectal cancer
- No history of familial adenomatous polyposis
- More than 5 years since prior flexible sigmoidoscopy
- No prior colonoscopy
- PATIENT CHARACTERISTICS:
- Age
- 50 to 69 (40 to 69 at the Louisiana State University participating site)
- Performance status
- Not specified
- Life expectancy
- Not specified
- Hematopoietic
- Not specified
- Hepatic
- Not specified
- Renal
- Not specified
- Cardiovascular
- No myocardial infarction within the past year
- No congestive heart failure
- Pulmonary
- No chronic obstructive pulmonary disease
- Gastrointestinal
- No history of ulcerative colitis
- No history of Crohn's disease
- No history of inflammatory bowel disease
- Other
- No serious comorbid condition
- No consumption of red meat within 3 days prior to and during FOBT (feasibility study II, arm II only)
- PRIOR CONCURRENT THERAPY:
- Biologic therapy
- Not specified
- Chemotherapy
- No concurrent chemotherapy other than for nonmelanoma skin cancer
- Endocrine therapy
- Not specified
- Radiotherapy
- Not specified
- Surgery
- Not specified
- Other
- No vitamin C consumption \> 250 mg within 3 days prior to and during fecal occult blood testing (FOBT) (feasibility study II arm II only)
- No nonsteroidal anti-inflammatory drugs within 7 days prior to and during FOBT (feasibility study II, arm II only)
- No concurrent anticoagulants
- No concurrent anticancer therapy except for treatment of nonmelanoma skin cancer
Age in the registry: 40 years to 69 years · Sex: All · Accepts healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Masonic Cancer Center at University of Minnesota (Data collection only) Coordinator of this site? Confirm its status | Minneapolis | United States | Unknown status |
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
| Kaiser Permanente Washington Health Research Institute (Data collection only) Coordinator of this site? Confirm its status | Seattle | United States | Unknown status |
| Feist-Weiller Cancer Center at Louisiana State University Health Sciences Coordinator of this site? Confirm its status | Shreveport | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.